Mass General Brigham's new AI intake agent inside MyChart routes primary-care patients to appointments, with the health system reporting 77% of users get seen the same day they report a new concern.
Google has replaced the Fitbit app with Google Health, adding a Gemini-powered AI coach that summarizes medical records and answers health questions as wearable makers race to become AI health platforms.
Whoop's $575 million Series G, backed by Abbott and Mayo Clinic, pushes its valuation to $10.1 billion as wearable makers race to reposition continuous health tracking as a clinical, not just fitness, tool.
Northwestern Medicine embedded OpenEvidence's AI clinical guidance directly into its Epic electronic health record, letting physicians check dosing and treatment guidelines without leaving the patient chart.
AstraZeneca signed a deal worth up to $1.5 billion with AI drug discovery startup insitro targeting liver and heart disease, paying just $40 million upfront with the rest tied to development milestones.
The FDA's comment period on a preliminary framework for regulating generative-AI medical devices closes October 19, even as a citizen petition challenges whether such AI tools fall under the agency's jurisdiction at all.
EliseAI raised $350 million at a $4 billion valuation, nearly doubling its year-earlier mark, as the AI agent company pushes further into healthcare operations alongside its established housing automation business.
Swedish digital health provider Yazen's $56 million round, led by Verdane, shows continued European investor appetite for technology-enabled care models amid aging populations.
OpenAI says 230 million people ask ChatGPT health questions weekly, as its dedicated Health feature expands to pull records from One Medical, Kaiser Permanente and Apple Health — raising questions about AI's growing role in informal medical advice.
Utah's Medical Licensing Board has demanded suspension of a state-sanctioned pilot letting Doctronic's AI renew prescriptions, citing safety concerns and reigniting debate over whether such tools fall under FDA medical device jurisdiction.